Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Bowden

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Nature Medicine|April 26, 2016
Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profilesPaloma Cejas, Lewyn Li, Nicholas K O'Neill, et al.
Nature Genetics|September 25, 2019
Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'Mariano J Alvarez, Pengrong Yan, Mary L Alpaugh, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Nature Communications|October 25, 2017
High grade serous ovarian carcinomas originate in the fallopian tubeS Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Nature Medicine|September 11, 2019
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Nature Medicine|July 3, 2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
The New England Journal of Medicine|July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Nature Medicine|April 26, 2016
Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profilesPaloma Cejas, Lewyn Li, Nicholas K O'Neill, et al.
Nature Genetics|September 25, 2019
Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'Mariano J Alvarez, Pengrong Yan, Mary L Alpaugh, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Nature Communications|October 25, 2017
High grade serous ovarian carcinomas originate in the fallopian tubeS Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Nature Medicine|September 11, 2019
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Nature Medicine|July 3, 2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
The New England Journal of Medicine|July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Pageof 6